A comparative analysis of BCR::ABL1 transcript and fusion gene copy numbers in 64 pediatric CML patients where sufficient material was available for additional DNA-based quantification, revealed overall comparable kinetics for both molecular markers during imatinib therapy. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.